| Name | Title | Contact Details |
|---|
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
SKIDMORE MEDICAL, LIMITED is a Evergreen, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Repro-Med Systems, Inc., operating as RMS Medical products, is a leading developer and manufacturer of medical devices and supplies. Repro-Med was incorporated in March, 1980. Its stock is publicly traded in the over-the-counter market and is quoted through the National Daily Quotation Service. Its stock symbol is REPR. The company maintains offices, manufacturing facilities, and warehouse space in Chester, New York. Devices and supplies manufactured and sold by RMS Medical Products are subject to Food and Drug Administration regulation. Our manufacturing facilities and record-keeping must meet FDA standards, and are subject to periodic FDA inspection. In addition, the company's plant is certified by the appropriate ISO international standards for quality in product development, manufacturing, distribution and customer support of its medical devices. RMS manufactures medical devices used in emergency care, hospital settings, nursing homes, other medical facilities and home care. The Company's principal products are the FREEDOM60 Syringe Infusion System and the RES-Q-VAC Emergency Medical Suction System. In 2011, the company received FDA approval to market in the U.S. it's HIgH-Flo RMS Subcutaneous Needle Sets. Since 1986, the company has owned and marketed the Gyneco product line which includes the Masterson Endometrial Biopsy Kit used for in-office biopsy sampling procedures, and the Thermal Cautery System used for tubal ligation procedures. RMS maintains its own sales staff in addition to selling its products through distributors in the U.S. and many other countries. It regularly exhibits at both national and international trade shows. The company holds a number of patents related to products it has developed and is manufacturing. Because Repro-Med Systems, Inc., is a public company, it must comply with financial reporting and other regulations established by the Securities and Exchange Commission.
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for "Best Explosives Detection Solution".
Neural Analytics was created in 2013 when the company`s co-founders were introduced to leading-edge technology in the UCLA Department of Neurology. Leo, Robert and Dan, along with key UCLA faculty and administrators, all saw the potential to commercialize this new technology and build an important company with the potential to help millions of patients around the world.